HC Wainwright Has Negative Estimate for VIR FY2029 Earnings

Vir Biotechnology, Inc. (NASDAQ:VIR) – Investment analysts at HC Wainwright lowered their FY2029 earnings per share estimates for shares of Vir Biotechnology in a research report issued to clients and investors on Friday, January 31st. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of $2.25 per share for the year, down from their prior forecast of $2.56. HC Wainwright currently has a “Buy” rating and a $110.00 price target on the stock. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($3.92) per share.

A number of other brokerages also recently weighed in on VIR. JPMorgan Chase & Co. lifted their price target on Vir Biotechnology from $10.00 to $14.00 and gave the company a “neutral” rating in a report on Thursday, January 9th. Barclays lowered their price target on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Morgan Stanley upgraded Vir Biotechnology from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $10.00 to $20.00 in a report on Thursday, January 9th. Leerink Partners lifted their price target on Vir Biotechnology from $18.00 to $20.00 and gave the company an “outperform” rating in a report on Monday, January 13th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $19.00 price target on shares of Vir Biotechnology in a report on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Vir Biotechnology currently has an average rating of “Moderate Buy” and a consensus target price of $34.83.

Vir Biotechnology Stock Down 2.9 %

Shares of NASDAQ VIR opened at $9.69 on Monday. Vir Biotechnology has a 52-week low of $6.56 and a 52-week high of $14.45. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of -2.47 and a beta of 0.51. The stock’s fifty day simple moving average is $8.90 and its 200 day simple moving average is $8.50.

Insider Activity at Vir Biotechnology

In other Vir Biotechnology news, Director Vicki L. Sato sold 10,960 shares of the business’s stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total value of $137,219.20. Following the completion of the sale, the director now owns 1,312,391 shares of the company’s stock, valued at $16,431,135.32. The trade was a 0.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 15.60% of the company’s stock.

Institutional Trading of Vir Biotechnology

A number of institutional investors and hedge funds have recently made changes to their positions in VIR. State Street Corp lifted its position in shares of Vir Biotechnology by 10.4% during the 3rd quarter. State Street Corp now owns 5,625,533 shares of the company’s stock worth $42,135,000 after purchasing an additional 530,645 shares during the last quarter. Millennium Management LLC lifted its position in shares of Vir Biotechnology by 94.6% during the 2nd quarter. Millennium Management LLC now owns 1,248,131 shares of the company’s stock worth $11,108,000 after purchasing an additional 606,804 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Vir Biotechnology by 13.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,134,276 shares of the company’s stock worth $8,496,000 after purchasing an additional 136,087 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Vir Biotechnology by 10.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 637,486 shares of the company’s stock worth $5,673,000 after purchasing an additional 58,360 shares during the last quarter. Finally, Barclays PLC lifted its position in shares of Vir Biotechnology by 1.3% during the 3rd quarter. Barclays PLC now owns 550,186 shares of the company’s stock worth $4,121,000 after purchasing an additional 7,287 shares during the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).